Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

1-20 of 306 trials

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPsychiatry

Corneal Transplantation: Optimized Immunosuppression Study

We are testing new immunosuppressive protocols for patients receiving corneal transplants to see if they can reduce eye pressure and cell loss. We also want to understand patient experiences and the cost-effectiveness of these treatments.

Corneal Graft Failure1-2 yearsMonitoring phase (IV)11-15 visits No Placebo Standard Medicines Cost ReimbursementOphthalmology

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Cost ReimbursementInternal MedicineNephrology

Epidermolysis Bullosa: ABCB5+ Stem Cell Treatment

We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.

Epidermolysis Bullosa1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteDermatologyInternal Medicine

Parkinson's Disease: ACI-7104.056 Vaccine Study

We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.

Early Stages of Parkinson's Disease>2 yearsEfficacy phase (II)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Etrasimod for Adolescents with Ulcerative Colitis

We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

Plaque Psoriasis>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesAllergologyDermatology

Glioblastoma: Early Intensified Treatment with Temozolomide

We are studying whether starting chemotherapy earlier with temozolomide helps adults with glioblastoma live longer compared to standard treatment. The trial also examines safety and treatment effectiveness.

Glioblastoma>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesNeurologyOncology

Marstacimab for Pediatric Hemophilia

We are studying a new treatment for children with severe hemophilia A or B to see if it is safer and more effective than standard care. This trial includes participants with or without inhibitors.

Haemophilia1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematology

Type 1 Diabetes: Frexalimab Treatment Study

We are studying a new medication, frexalimab, to see if it helps preserve insulin production in young people with newly diagnosed type 1 diabetes. Participants will receive either the medication or a placebo while continuing their insulin therapy.

Type 1 Diabetes1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational MedicinesEndocrinologyInternal Medicine

BOTOX for Masseter Muscle Prominence

We are studying whether BOTOX injections can help reduce the prominence of the masseter muscle in adults. This trial compares BOTOX to a placebo to evaluate its effectiveness and safety.

Masseter Muscle Prominence1-2 yearsConfirmation phase (III)11-15 visits Standard Medicines Cost ReimbursementDermatology

Systemic Lupus Erythematosus: Deucravacitinib Study

We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.

Active Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visits No Placebo Standard Medicines Partially RemoteOncology

Cirrhosis and Ascites: Personalized Human Albumin Treatment

We are studying a tailored approach to human albumin therapy for patients with liver cirrhosis and fluid buildup. The goal is to identify who may respond best to this treatment.

Liver Cirrhosis>2 yearsConfirmation phase (III)11-15 visits Standard Medicines Cost ReimbursementHepatologyInternal Medicine

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visits Standard Medicines Partially RemoteNephrologyRheumatology

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Ulcerative Colitis: GS-5290 Medication Study

We are testing a new medication for people with moderately to severely active ulcerative colitis to see if it helps improve symptoms better than a placebo. The study will assess various measures of clinical response and remission.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visits Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteNephrology

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Ovarian Cancer Treatment: Carboplatin and Mirvetuximab Soravtansine

We are studying a combination of carboplatin and a new drug, Mirvetuximab soravtansine, for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. This trial aims to see if this treatment improves response rates in patients with specific tumor characteristics.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Search Clinical Trials in the European Union